Retinal vein occlusion Market: Epidemiology, Therapies, Companies, DelveInsight | AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences Inc, Chugai Pharmaceuticals

Retinal vein occlusion therapies, such as VABYSMO (faricimab), LUCENTIS (ranibizumab), EYLEA (aflibercept), OZURDEX (dexamethasone intravitreal implant), Tarcocimab tedromer (KSI-301), LYTENAVA (bevacizumab)/ONS-5010, and others, are expected to boost the Retinal vein occlusion Market in the upcoming years.

DelveInsight has launched a new report on "Retinal vein occlusion - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Retinal vein occlusion, historical and forecasted epidemiology as well as the Retinal vein occlusion market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Retinal vein occlusion market report @ https://www.delveinsight.com/report-store/retinal-vein-occlusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Retinal vein occlusion Market Report:

The Retinal Vein Occlusion (RVO) market was valued at approximately USD 2.3 billion in the 7MM in 2022 and is expected to grow during the forecast period (2023-2034). In the US, the market size was around USD 1.6 billion, with an increase projected due to rising awareness and the introduction of new therapies. The EU4 and UK accounted for about USD 454 million, while Japan generated USD 232 million in RVO market revenue.
The growing geriatric population and increasing awareness of eye diseases are contributing to the rising prevalence of RVO. Current treatment options, including anti-VEGFs, corticosteroids, and laser therapy, aim to minimize damage but do not restore vision in the long term. There is a significant need for therapies that address the root cause, stop progression, and potentially eliminate the need for long-term treatments.
EYLEA (aflibercept) dominates the RVO treatment market, but the entry of biosimilars and newer drugs like VABYSMO (faricimab) is expected to shift the landscape. VABYSMO, approved in 2023, offers improved dosing and better outcomes for vision loss, positioning Roche to regain market share. Emerging therapies such as tarcocimab tedromer (KSI-301) and LYTENAVA (ONS-5010) are in late-stage development and could transform the market.
However, the market faces challenges due to the loss of patent exclusivity and the approval of biosimilars, which may limit the success of new therapies.
In 2022, the US represented approximately 61% of the total diagnosed prevalent cases of Retinal Vein Occlusion among the 7MM, with nearly 935,343 cases. This number is expected to rise throughout the study period (2020-2034).
According to DelveInsight analysis, the EU4 and the UK collectively accounted for about 408,086 diagnosed prevalent cases of Retinal Vein Occlusion in 2022. This figure is anticipated to change during the study period (2020-2034).
In January 2025, AI Optics Inc. received FDA 510(k) clearance for its Sentinel Camera, a portable, handheld retinal imaging system. This device is designed for point-of-care use, offering non-dilated imaging and being affordable and suitable for primary care, optometry, retail clinics, and home health settings.
In December 2024, Regeneron Pharmaceuticals announced that the primary endpoint was achieved in the Phase 3 QUASAR trial evaluating EYLEA HD® (aflibercept) Injection 8 mg for treating macular edema resulting from retinal vein occlusion (RVO), including central, branch, and hemiretinal vein occlusions.
Key Retinal vein occlusion companies such as AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences Inc, Chugai Pharmaceuticals, and others are evaluating new drugs for Retinal vein occlusion to improve the treatment landscape.
Promising Retinal vein occlusion therapies include VABYSMO (faricimab), LUCENTIS (ranibizumab), EYLEA (aflibercept), OZURDEX (dexamethasone intravitreal implant), Tarcocimab tedromer (KSI-301), LYTENAVA (bevacizumab)/ONS-5010, and others.

Retinal vein occlusion Overview

Retinal Vein Occlusion (RVO), the second most common retinal vascular disorder after diabetic retinopathy, occurs when small veins that carry blood from the retina become blocked. Often triggered by atherosclerosis and blood clots, RVO results in sudden changes in vision, with the extent of change depending on the severity and location of the blockage. The blockage causes pressure buildup in the capillaries, leading to hemorrhage and fluid leakage, which can result in macular edema near the macula.

Risk factors include systemic conditions such as hypertension, arteriosclerosis, diabetes, hyperlipidemia, stroke, blood hyperviscosity, and thrombophilia. People with end-organ damage are at a significantly higher risk. Ocular risk factors include ocular hypertension, glaucoma, high ocular perfusion pressure, and changes in the retinal arteries.

RVO is classified into central Retinal Vein Occlusion (CRVO) and branch Retinal Vein Occlusion (BRVO) based on the location of the blockage. CRVO is further divided into nonischemic and ischemic types based on perfusion, while BRVO is categorized into major branch RVO (blockage near or at the optic disc) and macular branch RVO (blockage in one of the macular venules).

RVO is common in elderly patients, particularly those over 65, with age and systemic vascular disorders being the main risk factors. As the geriatric population grows, the prevalence of RVO is expected to rise. Macular edema is a major complication causing vision loss in CRVO and BRVO patients, and various treatments are used to reduce macular edema and reverse intraocular neovascularization.

Retinal vein occlusion Market Outlook

Retinal Vein Occlusion is a common retinal vascular disorder and one of the leading causes of vision loss globally. It is the second most frequent cause of blindness from retinal vascular diseases, following diabetic retinopathy. Currently, no treatment can reverse Retinal Vein Occlusion, and most individuals with this condition will experience permanent vision changes. The primary treatment goal is to stabilize vision by sealing leaking blood vessels.

While it is not possible to unblock the retinal veins, doctors can manage associated health issues linked to the condition. In some cases, vision may improve in affected eyes. About one-third of patients experience some improvement, another third remain stable, and the remaining third show gradual improvement, though it can take up to a year or more to determine the outcome. In certain cases, the blocked vessels may lead to fluid buildup in the retina or trigger the growth of new blood vessels.

Discover how the Retinal vein occlusion market is rising in the coming years @ https://www.delveinsight.com/sample-request/retinal-vein-occlusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Retinal Vein Occlusion Marketed Drugs
VABYSMO (faricimab): Roche/Chugai Pharmaceutical
LUCENTIS (ranibizumab): Roche/Novartis
EYLEA (aflibercept): Regeneron Pharmaceutical/Bayer/Santen
OZURDEX (dexamethasone intravitreal implant): AbbVie

Retinal vein occlusion Emerging Drugs
Tarcocimab tedromer (KSI-301): Kodiak Sciences
LYTENAVA (bevacizumab)/ONS-5010: Outlook Therapeutics

Scope of the Retinal vein occlusion Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Retinal vein occlusion Companies: AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences Inc, Chugai Pharmaceuticals, and others
Key Retinal vein occlusion Therapies: VABYSMO (faricimab), LUCENTIS (ranibizumab), EYLEA (aflibercept), OZURDEX (dexamethasone intravitreal implant), Tarcocimab tedromer (KSI-301), LYTENAVA (bevacizumab)/ONS-5010, and others
Retinal vein occlusion Therapeutic Assessment: Retinal vein occlusion current marketed and Retinal vein occlusion emerging therapies
Retinal vein occlusion Market Dynamics: Retinal vein occlusion market drivers and Retinal vein occlusion market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Retinal vein occlusion Unmet Needs, KOL's views, Analyst's views, Retinal vein occlusion Market Access and Reimbursement

To know what's more in our Retinal vein occlusion report, visit https://www.delveinsight.com/report-store/retinal-vein-occlusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Retinal vein occlusion Market Report:
Retinal vein occlusion market report covers a descriptive overview and comprehensive insight of the Retinal vein occlusion Epidemiology and Retinal vein occlusion market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Retinal vein occlusion market report provides insights into the current and emerging therapies.
The Retinal vein occlusion market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Retinal vein occlusion market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Retinal vein occlusion market.

Got queries? Click here to know more about the Retinal vein occlusion market Landscape https://www.delveinsight.com/sample-request/retinal-vein-occlusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Retinal vein occlusion Patient Share (%) Overview at a Glance
5. Retinal vein occlusion Market Overview at a Glance
6. Retinal vein occlusion Disease Background and Overview
7. Retinal vein occlusion Epidemiology and Patient Population
8. Country-Specific Patient Population of Retinal vein occlusion
9. Retinal vein occlusion Current Treatment and Medical Practices
10. Unmet Needs
11. Retinal vein occlusion Emerging Therapies
12. Retinal vein occlusion Market Outlook
13. Country-Wise Retinal vein occlusion Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Retinal vein occlusion Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Retinal vein occlusion Market Outlook 2034 https://www.delveinsight.com/report-store/retinal-vein-occlusion-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Retinal vein occlusion Pipeline Insights, DelveInsight

"Retinal vein occlusion Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Retinal vein occlusion market. A detailed picture of the Retinal vein occlusion pipeline landscape is provided, which includes the disease overview and Retinal vein occlusion treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.